Savara (SVRA) Amortizatization of Intangibles (2012 - 2026)
Savara (SVRA) reported Amortizatization of Intangibles of $42000.0 for Q1 2026, down 96.34% year-over-year from $1.1 million in Q1 2025, and down 98.47% quarter-over-quarter from $2.7 million in Q4 2025.
Savara (SVRA) Amortizatization of Intangibles (2012 - 2026) Analysis & Trends
Savara (SVRA) has 9 years of Amortizatization of Intangibles data on file, last reported at $42000.0 in Q1 2026.
- Amortizatization of Intangibles for Q1 2026 came in at $42000.0, down 96.34% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 million (down 66.31% YoY), and the FY2025 annual result was $2.9 million, down 47.34% from the prior year.
- Amortizatization of Intangibles retreated to $42000.0 in Q1 2026 per SVRA's latest filing, from $2.7 million in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $5.3 million in Q4 2024 and troughed at -$1.3 million in Q2 2024.
- A 5-year average of $779941.2 and a median of $42000.0 in 2026 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2022 and 2024: Amortizatization of Intangibles plunged 568.42% in 2022, then jumped 9033.33% in 2024.
- A 5-year view of Amortizatization of Intangibles shows it stood at $357000.0 in 2022, then surged by 359.1% to $1.6 million in 2023, then soared by 225.5% to $5.3 million in 2024, then tumbled by 48.49% to $2.7 million in 2025, then plunged by 98.47% to $42000.0 in 2026.
- Business Quant data shows SVRA's Amortizatization of Intangibles at $42000.0 in Q1 2026, $2.7 million in Q4 2025, and $40000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Savara | 1.33 Bn | 1.33 Bn | - | 42,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42,000.00 |
| Mar 31, 2026 | 42,000.00 |
| Dec 31, 2025 | 2.75 Mn |
| Dec 31, 2025 | 2.75 Mn |
| Sep 30, 2025 | 40,000.00 |
| Sep 30, 2025 | 40,000.00 |
| Jun 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Mar 31, 2025 | 1.15 Mn |
| Dec 31, 2024 | 5.34 Mn |
| Dec 31, 2024 | 5.34 Mn |
| Sep 30, 2024 | 36,000.00 |
| Sep 30, 2024 | 36,000.00 |
| Jun 30, 2024 | -1.30 Mn |
| Jun 30, 2024 | -1.30 Mn |
| Mar 31, 2024 | 1.37 Mn |
| Mar 31, 2024 | 1.37 Mn |
| Dec 31, 2023 | 1.64 Mn |
| Dec 31, 2023 | 1.64 Mn |